ABT-348 + ABT-348 + ABT-348 and azacitidine + ABT-348
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Lymphoblastic Leukemia
Conditions
Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, B-cell Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Myelodysplasia
Trial Timeline
Apr 1, 2010 → Jun 1, 2013
NCT ID
NCT01110473About ABT-348 + ABT-348 + ABT-348 and azacitidine + ABT-348
ABT-348 + ABT-348 + ABT-348 and azacitidine + ABT-348 is a phase 1 stage product being developed by AbbVie for Acute Lymphoblastic Leukemia. The current trial status is completed. This product is registered under clinical trial identifier NCT01110473. Target conditions include Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, B-cell Chronic Lymphocytic Leukemia.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01110473 | Phase 1 | Completed |
Competing Products
20 competing products in Acute Lymphoblastic Leukemia